ArticleVirology journal2026
miR-194-5p targets SOCS2 to predict pegIFNα treatment response in HBeAg-positive chronic hepatitis B patients.
Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Predictive value and mechanism of LINC00665 for liver dysfunction in pregnant women with hepatitis B during early pregnancy.Virology journal · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic hepatitis B (CHB) with positive HBeAg status constitutes a significant contributor to the development of liver cirrhosis and hepatocellular carcinoma. Pegylated interferon-alpha (pegIFNα) is a common treatment, but its response rate remains limited, and the underlying mechanisms are not fully understood.
methodsEighty-two HBeAg-positive CHB patients were enrolled. miR-194-5p expression, HBeAg, and HBV DNA levels were detected using qRT-PCR, ELISA, and quantitative PCR, respectively. ROC and logistic regression analyses were performed. Cellular experiments, including dual-luciferase reporter and rescue assays, along with Western blot analysis of JAK-STAT pathway proteins, were conducted to verify targeting and function.
resultsComplete response (CR) patients had significantly lower baseline HBV DNA than suboptimal response (SR) patients. After 48 weeks of pegIFNα therapy, miR-194-5p expression decreased notably in the CR group and correlated positively with HBV DNA and HBeAg levels. miR-194-5p predicted treatment response with an AUC of 0.831 and was an independent predictor. Mechanistically, miR-194-5p targeted SOCS2. Functional studies demonstrated that miR-194-5p overexpression enhanced, while SOCS2 supplementation attenuated, pegIFNα-induced phosphorylation of STAT1/STAT2, thereby influencing cell viability and inflammatory factor expression (TNF-α, IL-6, IL-1β).
conclusionmiR-194-5p may predict pegIFNα response in HBeAg-positive CHB. It regulates interferon signaling by targeting SOCS2 and modulating the JAK-STAT pathway activation, suggesting the miR-194-5p/SOCS2 axis as a potential therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.